{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:51:48Z","timestamp":1759366308891,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.revmed.2005.07.002","type":"journal-article","created":{"date-parts":[[2005,8,12]],"date-time":"2005-08-12T07:38:16Z","timestamp":1123832296000},"page":"947-955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Traitement de la thrombocyth\u00e9mie essentielle"],"prefix":"10.1016","volume":"26","author":[{"given":"R.","family":"Costello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"O'Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"S\u00e9bahoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2005.07.002_bib1","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2005.07.002_bib2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0025-6196(12)61342-1","article-title":"Issues in the diagnosis and management of essential thrombocythemia","volume":"69","author":"Tefferi","year":"1994","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.revmed.2005.07.002_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.07.002_bib4","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0301-472X(01)00640-3","article-title":"Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia","volume":"29","author":"Chiusolo","year":"2001","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib5","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V100.5.1596.h81702001596_1596_1601","article-title":"Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia","volume":"100","author":"Shih","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2005.07.002_bib6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1055\/s-0037-1613087","article-title":"Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis","volume":"87","author":"Harrison","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.revmed.2005.07.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10153","article-title":"Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia","volume":"71","author":"Ruggeri","year":"2002","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1034\/j.1600-0609.2003.00079.x","article-title":"The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia","volume":"70","author":"Johansson","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V100.2.714","article-title":"The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia","volume":"100","author":"Teofili","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2005.07.002_bib10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2141.2004.05175.x","article-title":"PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythemia","volume":"127","author":"Vannucchi","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0009-9260(89)80092-3","article-title":"The treatment of essential thrombocythaemia with radioactive phosphorus","volume":"40","author":"Wagner","year":"1989","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.revmed.2005.07.002_bib12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1259\/bjr.70.839.9536909","article-title":"Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32--a 15\u00a0year review","volume":"70","author":"Balan","year":"1997","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.revmed.2005.07.002_bib13","first-page":"1495","article-title":"Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report","volume":"66","author":"Murphy","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.revmed.2005.07.002_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0609.1995.tb01621.x","article-title":"Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?","volume":"54","author":"Brandt","year":"1995","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib15","first-page":"461","article-title":"Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P)","volume":"117","author":"Randi","year":"1990","journal-title":"Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch."},{"key":"10.1016\/j.revmed.2005.07.002_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.1986.tb02926.x","article-title":"Primary thrombocythaemia treated with busulphan","volume":"62","author":"Van de Pette","year":"1986","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2141.2000.01951.x","article-title":"Short course of busulphan in essential thrombocythaemia: remodelling of an old strategy","volume":"109","author":"Berrebi","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-0609.1985.tb02270.x","article-title":"Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis","volume":"35","author":"de Pauw","year":"1985","journal-title":"Scand. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib19","first-page":"306","article-title":"Pipobroman therapy of essential thrombocythemia","volume":"37","author":"Mazzucconi","year":"1986","journal-title":"Scand. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.0007-1048.2002.03367.x","article-title":"Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis","volume":"116","author":"Passamonti","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00277-004-0882-7","article-title":"Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman","volume":"83","author":"Passamonti","year":"2004","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib22","first-page":"1339","article-title":"Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients","volume":"68","author":"Brusamolino","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.revmed.2005.07.002_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2005.07.002_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1365-2141.2002.3346_1.x","article-title":"Second malignancies in patients with essential thrombocythaemia","volume":"116","author":"Randi","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/1097-0142(19950115)75:2<471::AID-CNCR2820750210>3.0.CO;2-B","article-title":"Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent","volume":"75","author":"Higuchi","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2005.07.002_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/jjco\/hyd084","article-title":"Essential thrombocythemia transformed to acute myelogenous leukemia with t(3;17)(p24; q12), del(5)(q13q34) after treatment with carboquone and hydroxyurea","volume":"30","author":"Tabata","year":"2000","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.07.002_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajh.2830300112","article-title":"Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with melphalan","volume":"30","author":"Gris","year":"1989","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib29","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2005.07.002_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0369-8114(00)00024-9","article-title":"Efficacy and safety of hydroxyurea in patients with essential thrombocythemia","volume":"49","author":"Finazzi","year":"2001","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.revmed.2005.07.002_bib31","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/sj.leu.2402638","article-title":"Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea","volume":"16","author":"Bernasconi","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.revmed.2005.07.002_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/107602960000600307","article-title":"Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia","volume":"6","author":"Laguna","year":"2000","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.revmed.2005.07.002_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0609.1998.tb01064.x","article-title":"Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany","volume":"61","author":"Petrides","year":"1998","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib34","first-page":"315","article-title":"Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results","volume":"77","author":"Mazzucconi","year":"1992","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2005.07.002_bib35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide: a new drug for treating thrombocytosis","volume":"318","author":"Silverstein","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.07.002_bib36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2005.07.002_bib37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2257.2004.00637.x","article-title":"Anagrelide treatment in 52 patients with chronic myeloproliferative diseases","volume":"26","author":"Penninga","year":"2004","journal-title":"Clin. Lab. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib38","first-page":"1306","article-title":"A long-term study of young patients with essential thrombocythemia treated with anagrelide","volume":"89","author":"Mazzucconi","year":"2004","journal-title":"Haematologica"},{"issue":"Suppl 3","key":"10.1016\/j.revmed.2005.07.002_bib39","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1038\/sj.thj.6200438","article-title":"Management of the myeloproliferative disorders: distinguishing data from dogma","volume":"5","author":"Green","year":"2004","journal-title":"Hematol. J."},{"key":"10.1016\/j.revmed.2005.07.002_bib40","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","article-title":"Anagrelide for thrombocytosis in myeloproliferative disorders","volume":"101","author":"Steurer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2005.07.002_bib41","first-page":"1394","article-title":"Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocytemia","volume":"89","author":"Jurgens","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2005.07.002_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000204317","article-title":"Recombinant interferon alpha-2b as treatment of essential thrombocythaemia","volume":"91","author":"Rametta","year":"1994","journal-title":"Acta Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cncr.11486","article-title":"Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern cooperative oncology group","volume":"98","author":"Radin","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2005.07.002_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/030089169508100406","article-title":"Alpha interferon as initial treatment of essential thrombocythemia. Analysis after two years of follow-up","volume":"81","author":"Pogliani","year":"1995","journal-title":"Tumori"},{"key":"10.1016\/j.revmed.2005.07.002_bib45","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/sj.leu.2402597","article-title":"Nuclear factor-erythroid 2 (NF-E2) expression in normal and malignant megakaryocytopoiesis","volume":"16","author":"Catani","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2005.07.002_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00280-002-0533-4","article-title":"Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia","volume":"51","author":"Alvarado","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.revmed.2005.07.002_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0268-960X(98)90026-1","article-title":"The use of aspirin in polycythaemia vera and primary thrombocythaemia","volume":"12","author":"Willoughby","year":"1998","journal-title":"Blood Rev."},{"key":"10.1016\/j.revmed.2005.07.002_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","article-title":"Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin","volume":"97","author":"van Genderen","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2007-996110","article-title":"Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin","volume":"23","author":"Koudstaal","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.revmed.2005.07.002_bib50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/107602969900500210","article-title":"Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia","volume":"5","author":"Randi","year":"1999","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.revmed.2005.07.002_bib51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","article-title":"Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area","volume":"65","author":"Jensen","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.revmed.2005.07.002_bib52","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305003188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305003188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:13:55Z","timestamp":1759335235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866305003188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0248866305003188"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2005.07.002","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement de la thrombocyth\u00e9mie essentielle","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2005.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}